We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Connect Biopharma Holdings Ltd (CNTB) ADR EACH REPR 1 ORD SHS UNSPON

Sell:$1.73 Buy:$1.78 Change: $0.06 (3.49%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$1.73
Buy:$1.78
Change: $0.06 (3.49%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$1.73
Buy:$1.78
Change: $0.06 (3.49%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.

Contact details

Address:
12265 El Camino Real, Suite 350
SAN DIEGO
92130
United States
Telephone:
+1 (858) 7271040
Website:
https://www.connectbiopharm.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CNTB
ISIN:
US2075231017
Market cap:
$98.08 million
Shares in issue:
57.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Wubin Pan
    Chairman of the Board, President, Co-Founder
  • Zheng Wei
    Chief Executive Officer, Co-Founder, Director
  • Steven Chan
    Chief Financial Officer
  • Selwyn Ho
    Chief Business Officer
  • Chin Lee
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.